Upstream Bio Statistics
Total Valuation
Upstream Bio has a market cap or net worth of $537.67 million. The enterprise value is $197.43 million.
Important Dates
The next estimated earnings date is Tuesday, May 5, 2026, before market open.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Upstream Bio has 54.42 million shares outstanding. The number of shares has increased by 293.59% in one year.
| Current Share Class | 54.42M |
| Shares Outstanding | 54.42M |
| Shares Change (YoY) | +293.59% |
| Shares Change (QoQ) | +0.29% |
| Owned by Insiders (%) | 0.29% |
| Owned by Institutions (%) | 72.43% |
| Float | 34.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 188.39 |
| Forward PS | 297.07 |
| PB Ratio | 1.58 |
| P/TBV Ratio | 1.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 69.18 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 26.15, with a Debt / Equity ratio of 0.00.
| Current Ratio | 26.15 |
| Quick Ratio | 25.56 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -35.43% and return on invested capital (ROIC) is -24.66%.
| Return on Equity (ROE) | -35.43% |
| Return on Assets (ROA) | -23.99% |
| Return on Invested Capital (ROIC) | -24.66% |
| Return on Capital Employed (ROCE) | -47.12% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | $38,053 |
| Profits Per Employee | -$1.91M |
| Employee Count | 75 |
| Asset Turnover | 0.01 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +30.34% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | +30.34% |
| 50-Day Moving Average | 11.29 |
| 200-Day Moving Average | 18.98 |
| Relative Strength Index (RSI) | 46.79 |
| Average Volume (20 Days) | 806,386 |
Short Selling Information
The latest short interest is 3.44 million, so 6.31% of the outstanding shares have been sold short.
| Short Interest | 3.44M |
| Short Previous Month | 4.75M |
| Short % of Shares Out | 6.31% |
| Short % of Float | 9.93% |
| Short Ratio (days to cover) | 2.45 |
Income Statement
In the last 12 months, Upstream Bio had revenue of $2.85 million and -$143.44 million in losses. Loss per share was -$2.66.
| Revenue | 2.85M |
| Gross Profit | 2.85M |
| Operating Income | -160.36M |
| Pretax Income | -143.44M |
| Net Income | -143.44M |
| EBITDA | -160.17M |
| EBIT | -160.36M |
| Loss Per Share | -$2.66 |
Full Income StatementBalance Sheet
The company has $341.51 million in cash and $1.27 million in debt, with a net cash position of $340.24 million or $6.25 per share.
| Cash & Cash Equivalents | 341.51M |
| Total Debt | 1.27M |
| Net Cash | 340.24M |
| Net Cash Per Share | $6.25 |
| Equity (Book Value) | 339.77M |
| Book Value Per Share | 6.26 |
| Working Capital | 338.35M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$133.28 million and capital expenditures -$165,000, giving a free cash flow of -$133.44 million.
| Operating Cash Flow | -133.28M |
| Capital Expenditures | -165,000 |
| Depreciation & Amortization | 188,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -133.44M |
| FCF Per Share | -$2.45 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -5,618.82% |
| Pretax Margin | -5,026.03% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Upstream Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -293.59% |
| Shareholder Yield | n/a |
| Earnings Yield | -26.68% |
| FCF Yield | -24.82% |
Analyst Forecast
The average price target for Upstream Bio is $37.67, which is 281.28% higher than the current price. The consensus rating is "Buy".
| Price Target | $37.67 |
| Price Target Difference | 281.28% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 100.60% |
| EPS Growth Forecast (5Y) | 6.32% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Upstream Bio has an Altman Z-Score of 32.81 and a Piotroski F-Score of 1.
| Altman Z-Score | 32.81 |
| Piotroski F-Score | 1 |
